Emergent BioSolutions Inc. (FRA:ER4)

Germany flag Germany · Delayed Price · Currency is EUR
9.86
+0.60 (6.48%)
Last updated: Dec 4, 2025, 8:07 AM CET
5.98%
Market Cap 542.68M
Revenue (ttm) 672.38M
Net Income (ttm) 64.69M
Shares Out n/a
EPS (ttm) 1.15
PE Ratio 8.39
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 33
Open 9.86
Previous Close 9.26
Day's Range 9.86 - 9.86
52-Week Range 3.75 - 11.22
Beta n/a
RSI 59.36
Earnings Date Mar 5, 2026

About Emergent BioSolutions

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 900
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ER4
Full Company Profile

Financial Performance

In 2024, Emergent BioSolutions's revenue was $1.04 billion, a decrease of -0.54% compared to the previous year's $1.05 billion. Losses were -$190.60 million, -74.94% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.